Chairman Arne Ferstad and CEO Jan Nilsson have increased their shareholdings in CombiGene by 300,000 and 100,000 shares, respectively. The seller is the company’s majority owner, Lars Thunberg. The sale has been made at the current market price.
“The sale of shares in CombiGene to Arne Ferstad and Jan Nilsson is an excellent way of strengthening the ties between CombiGene and the company’s two key people,” says Lars Thunberg. “That the sale was transacted at the current market price demonstrates the great confidence Arne and Jan have in the future of CombiGene.”
“Gene therapy is currently one of the pharma industry’s most promising areas and has fantastic potential to revolutionize the treatment of a wide range of serious diseases. CombiGene’s project portfolio now includes two exciting projects: one for treatment of difficult-to-treat epilepsy and one for treatment of the rare disease lipodystrophy. CombiGene is now in a very interesting phase of development and our increase in holdings in the company reflects the positive expectations we have for the future,” commented CombiGene board chairman Arne Ferstad and CEO Jan Nilsson in a joint statement.